Specify a stock or a cryptocurrency in the search bar to get a summary
LifeTech Scientific Corp
1302LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders worldwide. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, HeartR, and Konar-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; Futhrough endovascular needle systems; delivery systems, such as Fustar steerable and SteerEase introducers; Zoetrack guidewire; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; HearTone implantable cardiac pacing system; and SeQure snare systems, as well as pacemakers. The company is also involved in the biomedical research and development; properties leasing business; and manufacturing and trading of medical devices, as well as offers technical, consulting, and technology services. The company was founded in 1999 and is headquartered in Shenzhen, China. Address: LifeTech Scientific Building, Shenzhen, China, 518063
Analytics
WallStreet Target Price
20.55 HKDP/E ratio
27.3333Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 1302
Dividend Analytics 1302
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 1302
Stock Valuation 1302
Financials 1302
Results | 2019 | Dynamics |